Abramson Cancer Center

Researchers

• CJCarl H June
• MRMarco Ruella
• SSSandra Susanibar-Adaniya

Running trials

• Not yet recruiting

  Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

  NCT07059611· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Not yet recruiting

  211At-MABG in Adults With Advanced Neuroendocrine Cancers

  NCT07661420· Phase 1· University of Pennsylvania· Source

• Not yet recruiting

  [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

  NCT07723651· Phase 2· Washington University School of Medicine· Source

• Not yet recruiting

  PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

  NCT07700121· Early phase 1· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

  NCT06770855· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

  NCT07478848· Phase 1· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Nutrition Intervention for Pancreatic Cancer

  NCT07554560· Children's Hospital of Philadelphia· Source

• Recruiting

  Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  NCT07340541· Phase 2· UNC Lineberger Comprehensive Cancer Center· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

  NCT06837480· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

  NCT07281430· National Cancer Institute (NCI)· Source

• Recruiting

  CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

  NCT07278986· Early phase 1· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Telehealth Collaborative Care Model (CoCM) in Lung Cancer

  NCT07102147· Abramson Cancer Center at Penn Medicine· Source

• Active, not recruiting

  Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

  NCT06732401· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

  NCT07048496· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  NCT07020221· Phase 1/2· Verastem, Inc.· Source

• Recruiting

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

  NCT06747845· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

  NCT06747390· Phase 1· Ryan Carey· Source

• Recruiting

  Healthy Volunteers Study

  NCT06962059· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

  NCT06731907· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

  NCT06708949· Phase 2· M.D. Anderson Cancer Center· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Recruiting

  Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

  NCT05077527· Phase 1· AIDS Malignancy Consortium· Source

• Active, not recruiting

  Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

  NCT06617923· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Active, not recruiting

  Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

  NCT06332131· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Immatics US, Inc.· Source

• Recruiting

  Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

  NCT06566079· Phase 1/2· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

  NCT06475989· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  NCT06369285· Phase 2· Puma Biotechnology, Inc.· Source

• Recruiting

  SynKIR-310 for Relapsed/Refractory B-NHL

  NCT06544265· Phase 1· Verismo Therapeutics· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Incyte Corporation· Source

• Recruiting

  QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

  NCT06551116· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Epcoritamab-CAR T Cells for Large B-cell Lymphomas

  NCT06458439· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Enrolling by invitation

  Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

  NCT06578637· Abramson Cancer Center at Penn Medicine· Source

• Active, not recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

  NCT06611553· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

  NCT06611540· National Cancer Institute (NCI)· Source

• Recruiting

  Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

  NCT05733598· Phase 2· Replimune, Inc.· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Recruiting

  A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

  NCT06362252· Phase 1/2· Daiichi Sankyo· Source

Showing 50 of 209.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer16 recruiting
• Ovarian cancer11 recruiting
• Pancreatic cancer11 recruiting
• Triple-negative breast cancer8 recruiting
• Diffuse large B-cell lymphoma7 recruiting
• Prostate cancer7 recruiting
• Endometrial cancer6 recruiting
• Follicular lymphoma6 recruiting
• Acute myeloid leukaemia5 recruiting
• Colorectal cancer5 recruiting
• Bladder cancer4 recruiting
• Childhood cancers4 recruiting
• Head and neck cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Gastric and oesophageal cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Mesothelioma3 recruiting
• Multiple myeloma3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Neuroendocrine tumours3 recruiting
• Sarcoma3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Kidney cancer2 recruiting
• Melanoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Meningioma1 recruiting

Closed trials

• Withdrawn

  Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

  NCT06337162· Phase 1· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

  NCT05883449· Phase 2· Affimed GmbH· Source

• Completed

  Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

  NCT05721326· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making

  NCT06463977· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

  NCT04593277· Fred Hutchinson Cancer Center· Source

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Phase 1· Navire Pharma Inc., a BridgeBio company· Source

• Completed

  XmAb20717 in Advanced Biliary Tract Cancers

  NCT05297903· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

  NCT04873895· Phase 1· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

  NCT05228015· Phase 1· Ikena Oncology· Source

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

  NCT04118530· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

  NCT04735068· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

  NCT04659044· Phase 2· Academic and Community Cancer Research United· Source

• Completed

  Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

  NCT04737265· Phase 1/2· Abramson Cancer Center at Penn Medicine· Source

• Completed

  KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  NCT04165083· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

  NCT04288687· Phase 2· Abramson Cancer Center at Penn Medicine· Source

• Completed

  HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

  NCT03685331· Phase 1· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

  NCT04353973· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

  NCT04305054· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

  NCT04305041· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

  NCT04303169· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

  NCT04305444· Phase 2· Zhejiang DTRM Biopharma· Source

• Completed

  A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

  NCT04229004· Phase 3· Pancreatic Cancer Action Network· Source

• Completed

  KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

  NCT04165096· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

  NCT05399004· Mayo Clinic· Source

• Completed

  Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

  NCT04023110· Phase 1· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

  NCT03975387· Phase 1· Taiho Oncology, Inc.· Source

• Completed

  A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

  NCT03752398· Phase 1· Xencor, Inc.· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

  NCT03960177· Early phase 1· OHSU Knight Cancer Institute· Source

• Terminated

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Phase 1· Inhibrx Biosciences, Inc· Source

• Completed

  Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

  NCT03710876· Phase 3· Ferring Ventures Limited· Source

• Completed

  Cardiovascular Function in Acute Leukemia

  NCT03760237· Abramson Cancer Center at Penn Medicine· Source

• Completed

  (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

  NCT03580655· Phase 2· Blueprint Medicines Corporation· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

  NCT03558087· Phase 2· Matthew Galsky· Source

• Terminated

  Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

  NCT03107780· Phase 1· National Cancer Institute (NCI)· Source

• Terminated

  In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

  NCT03492164· Early phase 1· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Personalized Radiation Therapy for GBM

  NCT03477513· Abramson Cancer Center at Penn Medicine· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

  NCT03404960· Phase 1/2· University of Pennsylvania· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02713386· Phase 1/2· NRG Oncology· Source

• Completed

  Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

  NCT02621398· Phase 1· Rutgers, The State University of New Jersey· Source

• Completed

  The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Completed

  FDG PET/CT in Lung Cancer Staging

  NCT02738398· Abramson Cancer Center at Penn Medicine· Source

• Terminated

  Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02408861· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Endocrine Response in Women With Invasive Lobular Breast Cancer

  NCT02206984· Phase 2· Priscilla McAuliffe· Source

• Completed

  Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02498600· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Takeda· Source

Showing 50 of 66.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma23 works · 9 trials
• Hodgkin lymphoma16 works · 4 trials
• Chronic lymphocytic leukaemia9 works · 6 trials
• Diffuse large B-cell lymphoma9 works · 11 trials
• Mantle cell lymphoma7 works · 6 trials
• Follicular lymphoma6 works · 10 trials